Advanced

Solitary juvenile xanthogranuloma in the spine pretreated with neoadjuvant denosumab therapy followed by surgical resection in a 5-year-old child : case report and literature review

Irmola, Tero ; Laitinen, Minna K. ; Parkkinen, Jyrki ; Engellau, Jacob LU and Neva, Marko H. (2018) In European Spine Journal p.1-6
Abstract

Purpose: We present a case report that describes neoadjuvant denosumab therapy initiated in a child with a solitary giant cell-rich juvenile xanthogranuloma tumor involving the spine, and review the current literature.Methods: A giant cell-rich histiocytic lesion involving the 11th thoracic vertebral body was identified in a healthy 5-year-old girl with persistent back and pelvic pain for several months. Imaging examinations and an open biopsy were performed to obtain a definite pathologic diagnosis. As the tumor appeared to be aggressive in nature, we administered adjuvant therapy with denosumab preoperatively and then performed a total spondylectomy.Results: Histopathology confirmed that the tumor was juvenile xanthogranuloma. No... (More)

Purpose: We present a case report that describes neoadjuvant denosumab therapy initiated in a child with a solitary giant cell-rich juvenile xanthogranuloma tumor involving the spine, and review the current literature.Methods: A giant cell-rich histiocytic lesion involving the 11th thoracic vertebral body was identified in a healthy 5-year-old girl with persistent back and pelvic pain for several months. Imaging examinations and an open biopsy were performed to obtain a definite pathologic diagnosis. As the tumor appeared to be aggressive in nature, we administered adjuvant therapy with denosumab preoperatively and then performed a total spondylectomy.Results: Histopathology confirmed that the tumor was juvenile xanthogranuloma. No tumor metastases or recurrence were detected at the 3-year follow-up, and the patient was asymptomatic. Conclusions: In giant cell-rich tumors, denosumab is occasionally used as neoadjuvant or adjuvant therapy, especially for tumors in difficult locations or with substantial soft tissue extensions. Rare adverse events in children include skin infections and disruption of calcium homeostasis. Surgical treatment is aimed at removing the tumor and relieving the symptomatic spinal cord compression. Use of denosumab as neoadjuvant therapy for juvenile xanthogranuloma involving the spine has not been reported previously.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; and
publishing date
type
Contribution to journal
publication status
epub
subject
keywords
Denosumab, Hypercalcemia, Spine, Tumor, Xanthogranuloma
in
European Spine Journal
pages
6 pages
publisher
Springer
external identifiers
  • pmid:29876657
  • scopus:85048060326
ISSN
0940-6719
DOI
10.1007/s00586-018-5651-8
language
English
LU publication?
no
id
a4560ddd-13e1-4fed-b765-69eab7ad65a0
date added to LUP
2018-06-19 12:36:39
date last changed
2020-11-16 02:30:34
@article{a4560ddd-13e1-4fed-b765-69eab7ad65a0,
  abstract     = {<p>Purpose: We present a case report that describes neoadjuvant denosumab therapy initiated in a child with a solitary giant cell-rich juvenile xanthogranuloma tumor involving the spine, and review the current literature.Methods: A giant cell-rich histiocytic lesion involving the 11th thoracic vertebral body was identified in a healthy 5-year-old girl with persistent back and pelvic pain for several months. Imaging examinations and an open biopsy were performed to obtain a definite pathologic diagnosis. As the tumor appeared to be aggressive in nature, we administered adjuvant therapy with denosumab preoperatively and then performed a total spondylectomy.Results: Histopathology confirmed that the tumor was juvenile xanthogranuloma. No tumor metastases or recurrence were detected at the 3-year follow-up, and the patient was asymptomatic. Conclusions: In giant cell-rich tumors, denosumab is occasionally used as neoadjuvant or adjuvant therapy, especially for tumors in difficult locations or with substantial soft tissue extensions. Rare adverse events in children include skin infections and disruption of calcium homeostasis. Surgical treatment is aimed at removing the tumor and relieving the symptomatic spinal cord compression. Use of denosumab as neoadjuvant therapy for juvenile xanthogranuloma involving the spine has not been reported previously.</p>},
  author       = {Irmola, Tero and Laitinen, Minna K. and Parkkinen, Jyrki and Engellau, Jacob and Neva, Marko H.},
  issn         = {0940-6719},
  language     = {eng},
  month        = {06},
  pages        = {1--6},
  publisher    = {Springer},
  series       = {European Spine Journal},
  title        = {Solitary juvenile xanthogranuloma in the spine pretreated with neoadjuvant denosumab therapy followed by surgical resection in a 5-year-old child : case report and literature review},
  url          = {http://dx.doi.org/10.1007/s00586-018-5651-8},
  doi          = {10.1007/s00586-018-5651-8},
  year         = {2018},
}